185 related articles for article (PubMed ID: 22929967)
1. Diclofenac delays micropore closure following microneedle treatment in human subjects.
Brogden NK; Milewski M; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Control Release; 2012 Oct; 163(2):220-9. PubMed ID: 22929967
[TBL] [Abstract][Full Text] [Related]
2. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.
Brogden NK; Banks SL; Crofford LJ; Stinchcomb AL
Pharm Res; 2013 Aug; 30(8):1947-55. PubMed ID: 23761054
[TBL] [Abstract][Full Text] [Related]
3. Micropore closure kinetics are delayed following microneedle insertion in elderly subjects.
Kelchen MN; Siefers KJ; Converse CC; Farley MJ; Holdren GO; Brogden NK
J Control Release; 2016 Mar; 225():294-300. PubMed ID: 26829102
[TBL] [Abstract][Full Text] [Related]
4. Micropore closure time is longer following microneedle application to skin of color.
Ogunjimi AT; Carr J; Lawson C; Ferguson N; Brogden NK
Sci Rep; 2020 Nov; 10(1):18963. PubMed ID: 33144596
[TBL] [Abstract][Full Text] [Related]
5. Micropore Closure Rates following Microneedle Application at Various Anatomical Sites in Healthy Human Subjects.
Ogunjimi AT; Lawson C; Carr J; Patel KK; Ferguson N; Brogden NK
Skin Pharmacol Physiol; 2021; 34(4):214-228. PubMed ID: 33910205
[TBL] [Abstract][Full Text] [Related]
6. Novel nano-in-micro fabrication technique of diclofenac nanoparticles loaded microneedle patches for localised and systemic drug delivery.
Li M; Vora LK; Peng K; Sabri AHB; Qin N; Abbate M; Paredes AJ; McCarthy HO; Donnelly RF
Biomater Adv; 2024 Jul; 161():213889. PubMed ID: 38781739
[TBL] [Abstract][Full Text] [Related]
7. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion.
Brogden NK; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Pharm Sci; 2013 Jun; 102(6):1948-1956. PubMed ID: 23589356
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.
Ghosh P; Brogden NK; Stinchcomb AL
J Pharm Sci; 2014 Feb; 103(2):652-60. PubMed ID: 24395718
[TBL] [Abstract][Full Text] [Related]
9. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
10. Skin Irritation and Sensitization Potential of Fixed-Dose Combination of Diclofenac 1% and Menthol 3% Topical Gel: Results of Two Phase I Patch Studies.
Liu DJ; Collaku A; Dosik JS
Drug Res (Stuttg); 2017 Feb; 67(2):119-126. PubMed ID: 27887033
[TBL] [Abstract][Full Text] [Related]
11. A crossover clinical study to evaluate pain intensity from microneedle insertion in different parts of the oral cavity.
Di Carla Santos S; Fávaro-Moreira NC; Abdalla HB; Augusto GGX; Costa YM; Volpato MC; Groppo FC; Gill HS; Franz-Montan M
Int J Pharm; 2021 Jan; 592():120050. PubMed ID: 33161036
[TBL] [Abstract][Full Text] [Related]
12. In vivo determination of the diclofenac skin reservoir: comparison between passive, occlusive, and iontophoretic application.
Clijsen R; Baeyens JP; Barel AO; Clarys P
Drug Des Devel Ther; 2015; 9():835-40. PubMed ID: 25709408
[TBL] [Abstract][Full Text] [Related]
13. Influence of the formulation on the in vitro transdermal penetration of sodium diclofenac. Evaluation of the topical and systemic anti-inflammatory activity in the rat.
Calpena AC; Escribano E; San Martin H; Lauroba J; Obach R; Domenech J
Arzneimittelforschung; 1999 Dec; 49(12):1012-7. PubMed ID: 10635447
[TBL] [Abstract][Full Text] [Related]
14. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
Banks SL; Paudel KS; Brogden NK; Loftin CD; Stinchcomb AL
Pharm Res; 2011 May; 28(5):1211-9. PubMed ID: 21301935
[TBL] [Abstract][Full Text] [Related]
15. Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation.
Gschwend MH; Martin W; Arnold P; Verdun MO; Cambon N; Frentzel A; Scheiwe W
Arzneimittelforschung; 2005; 55(7):403-13. PubMed ID: 16080280
[TBL] [Abstract][Full Text] [Related]
16. Qualitative and quantitative analysis of lateral diffusion of drugs in human skin.
Nguyen HX; Puri A; Bhattaccharjee SA; Banga AK
Int J Pharm; 2018 Jun; 544(1):62-74. PubMed ID: 29654897
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of diclofenac potassium at low doses.
Hinz B; Chevts J; Renner B; Wuttke H; Rau T; Schmidt A; Szelenyi I; Brune K; Werner U
Br J Clin Pharmacol; 2005 Jan; 59(1):80-4. PubMed ID: 15606444
[TBL] [Abstract][Full Text] [Related]
18. Effect of microporation on passive and iontophoretic delivery of diclofenac sodium.
Patel H; Joshi A; Joshi A; Stagni G
Drug Dev Ind Pharm; 2015; 41(12):1962-7. PubMed ID: 25758411
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous concentrations following topical iontophoretic delivery of diclofenac.
Kasha PC; Anderson CR; Morris RL; Sembrowich WL; Chaturvedula A; Banga AK
Drug Discov Ther; 2012 Oct; 6(5):256-62. PubMed ID: 23229146
[TBL] [Abstract][Full Text] [Related]
20. Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema.
Magnette JL; Kienzler JL; Sallin D; Ménart C; Nollevaux F; Knops A
Eur J Clin Pharmacol; 2004 Oct; 60(8):591-4. PubMed ID: 15455182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
